Department of Public Health and Caring Sciences, Section of Geriatrics, Uppsala University, Uppsala, Sweden.
JAMA. 2011 Sep 14;306(10):1113-21. doi: 10.1001/jama.2011.1246. Epub 2011 Aug 29.
Experimental data suggest that cathepsin S, a cysteine protease, is involved in the complex pathways leading to cardiovascular disease and cancer. However, prospective data concerning a potential association between circulating cathepsin S levels and mortality are lacking.
To investigate associations between circulating cathepsin S levels and mortality in 2 independent cohorts of elderly men and women.
DESIGN, SETTING, AND PARTICIPANTS: Prospective study using 2 community-based cohorts, the Uppsala Longitudinal Study of Adult Men (ULSAM; n = 1009; mean age: 71 years; baseline period: 1991-1995; median follow-up: 12.6 years; end of follow-up: 2006) and the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS; n = 987; 50% women; mean age: 70 years; baseline period: 2001-2004; median follow-up: 7.9 years; end of follow-up: 2010). Serum samples were used to measure cathepsin S.
Total mortality.
During follow-up, 413 participants died in the ULSAM cohort (incidence rate: 3.59/100 person-years at risk) and 100 participants died in the PIVUS cohort (incidence rate: 1.32/100 person-years at risk). In multivariable Cox regression models adjusted for age, systolic blood pressure, diabetes, smoking status, body mass index, total cholesterol, high-density lipoprotein cholesterol, antihypertensive treatment, lipid-lowering treatment, and history of cardiovascular disease, higher serum cathepsin S was associated with an increased risk for mortality (ULSAM cohort: hazard ratio [HR] for 1-unit increase of cathepsin S, 1.04 [95% CI, 1.01-1.06], P = .009; PIVUS cohort: HR for 1-unit increase of cathepsin S, 1.03 [95% CI, 1.00-1.07], P = .04). In the ULSAM cohort, serum cathepsin S also was associated with cardiovascular mortality (131 deaths; HR for quintile 5 vs quintiles 1-4, 1.62 [95% CI, 1.11-2.37]; P = .01) and cancer mortality (148 deaths; HR for 1-unit increase of cathepsin S, 1.05 [95% CI, 1.01-1.10]; P = .01).
Among elderly individuals in 2 independent cohorts, higher serum cathepsin S levels were associated with increased mortality risk. Additional research is needed to delineate the role of cathepsin S and whether its measurement might have clinical utility.
实验数据表明,组织蛋白酶 S 是一种半胱氨酸蛋白酶,它参与了导致心血管疾病和癌症的复杂途径。然而,关于循环组织蛋白酶 S 水平与死亡率之间潜在关联的前瞻性数据仍然缺乏。
在两个独立的老年男女队列中,研究循环组织蛋白酶 S 水平与死亡率之间的关联。
设计、地点和参与者:这是一项前瞻性研究,使用了两个基于社区的队列,乌普萨拉成年男性纵向研究(ULSAM;n = 1009;平均年龄:71 岁;基线期:1991-1995 年;中位随访期:12.6 年;随访结束:2006 年)和乌普萨拉老年人血管前瞻性研究(PIVUS;n = 987;50%为女性;平均年龄:70 岁;基线期:2001-2004 年;中位随访期:7.9 年;随访结束:2010 年)。血清样本用于测量组织蛋白酶 S。
总死亡率。
在随访期间,ULSAM 队列中有 413 名参与者死亡(发生率:每 100 人-年风险 3.59 人),PIVUS 队列中有 100 名参与者死亡(发生率:每 100 人-年风险 1.32 人)。在多变量 Cox 回归模型中,调整年龄、收缩压、糖尿病、吸烟状况、体重指数、总胆固醇、高密度脂蛋白胆固醇、降压治疗、降脂治疗和心血管疾病史后,较高的血清组织蛋白酶 S 与死亡率增加相关(ULSAM 队列:组织蛋白酶 S 增加 1 单位的风险比[HR],1.04[95%CI,1.01-1.06],P =.009;PIVUS 队列:组织蛋白酶 S 增加 1 单位的 HR,1.03[95%CI,1.00-1.07],P =.04)。在 ULSAM 队列中,血清组织蛋白酶 S 也与心血管死亡率(131 例死亡;第 5 五分位组与第 1-4 五分位组的 HR,1.62[95%CI,1.11-2.37];P =.01)和癌症死亡率(148 例死亡;组织蛋白酶 S 增加 1 单位的 HR,1.05[95%CI,1.01-1.10];P =.01)相关。
在两个独立的老年人群队列中,较高的血清组织蛋白酶 S 水平与死亡率升高相关。需要进一步研究以阐明组织蛋白酶 S 的作用,以及其测量是否具有临床应用价值。